A univariate analysis of the preoperative characteristics of patients treated with anatomical lung resection with full video-assisted thoracoscopic surgery or intraoperative conversion to thoracotomy
| Variable . | Full VATS group, n = 7100 . | Conversion group, n = 843 . | Odds ratio [95% CI] . | P-value . |
|---|---|---|---|---|
| Sex | <0.0001 | |||
| Female | 3032 (42.6 %) | 289 (34.2 %) | 1 | |
| Male | 4068 (57.3%) | 554 (65.8 %) | 1.42 [1.25–1.60] | |
| Age (years) | 69 ± 11.3 | 66.0 ± 9.7 | 1.012 [1.006–1.018] | 0.0002 |
| BMI (kg/m²) | 25.3 ± 4.6 | 26.2 ± 5.0 | 1.039 [1.026–1.052] | <0.0001 |
| WHO PS | 0.007 | |||
| 0 | 4366 (61.5%) | 497 (59.0%) | 1 | |
| 1 | 2385 (33.6 %) | 297 (35.5%) | 1.19 [1.05–1.35] | |
| 2 | 319 (4.5 %) | 44 (5.2%) | 1.14 [0.85–1.52] | |
| 3 | 28 (0.4%) | 4 (0.4%) | 1.93 [0.85–4.38] | |
| 4 | 0 (0%) | 1 (< 0.1%) | ||
| ASA status | <0.0001 | |||
| ASA 1-2 | 4785 (67.4%) | 520 (61.7%) | 1 | |
| ASA 3-4 | 2315 (32.6%) | 323 (38.3%) | 1.32 [1.17–1.50] | |
| History of smoking | 5495 (77.4%) | 697 (82.6%) | 1.22 [1.08–1.37] | 0.001 |
| Smoking (pack-years) | 30 ± 14.1 | 34.4 ± 25.0 | 1.005 [1.003–1.008] | <0.0001 |
| Preop. FEV1 | 90 ± 19.6 | 87.7 ± 19.3 | 0.993 [0.990–0.996] | <0.0001 |
| Induction CTx | 134 (1.9 %) | 19 (2.1%) | 0.809 | |
| Hypertension | 2201 (31 %) | 293 (34.8%) | 1.19 [1.05–1.35] | 0.007 |
| Pulmonary hypertension | 7 (< 0.1 %) | 1 (< 0.1%) | 0.275 | |
| Congestive heart failure | 28 (0.4 %) | 6 (0.7%) | 0.791 | |
| Peripheral arterial disease | 646 (9.1 %) | 110 (13.1%) | 1.37 [1.14–1.64] | 0.001 |
| Valvulopathy | 78 (1.1 %) | 14 (1.7%) | 1.74 [1.04–2.90] | 0.034 |
| Coronary artery disease | 646 (9.1 %) | 107 (12.7%) | 1.34 [1.11–1.63] | 0.003 |
| Cardiac arrhythmia | 475 (6.7 %) | 76 (9.1%) | 1.31 [1.04–1.64] | 0.022 |
| Previous cardiac surgery | 85 (1.2 %) | 18 (2.2%) | 1.75 [1.14–2.70] | 0.011 |
| Stroke | 244 (3.3 %) | 39 (4.6%) | 1.40 [1.04–1.88] | 0.025 |
| Antiplatelet therapy | 320 (4.5 %) | 53 (6.3%) | 1.45 [1.12–1.87] | 0.005 |
| Asthma | 128 (1.8 %) | 22 (2.5%) | 0.220 | |
| Sleep apnoea | 198 (2.8 %) | 26 (3.1%) | 0.674 | |
| Previous thoracic surgery | 142 (2.0 %) | 20 (2.4%) | 1.12 [0.77–1.63] | 0.541 |
| Previous thoracic trauma | 7 (< 0.1 %) | 6 (0.7%) | 3.34 [1.39–8] | 0.007 |
| Alcohol addiction | 334 (4.7 %) | 47 (5.6%) | 0.826 | |
| Chronic kidney failure | 134 (1.9%) | 33 (3.9%) | 2.32 [1.70–3.17] | <0.0001 |
| Malnutrition | 45 (0.6%) | 7 (0.9%) | 0.597 | |
| Thyroid dysfunction | 270 (3.8 %) | 34 (4.1%) | 0.295 | |
| Drug addiction | 45 (0.6 %) | 12 (1.4%) | 1.55 [0.81–2.94] | 0.186 |
| Chronic liver failure | 41 (0.6 %) | 7 (0.8%) | 0.527 | |
| Type II diabetes | 724 (10.2 %) | 130 (15.4%) | 1.42 [1.19–1.69] | <0.0001 |
| Histological analysis | <0.0001 | |||
| Primary lung | 6688 (94.2 %) | 811 (96.2%) | 1 | |
| Metastasis | 292 (4.1 %) | 24 (2.9%) | 0.63 [0.48–0.83] | |
| Benign | 120 (1.7 %) | 8 (0.9%) | 0.40 [0.23–0.69] | |
| Surgery side | ||||
| Right | 3684 (51.9%) | 423 (50.2%) | 0.257 | |
| Left | 3416 (48.1%) | 420 (49.8%) | ||
| Extent of resection | <0.0001 | |||
| Lobectomy | 5829 (82.1 %) | 722 (85.7%) | 1 | |
| Bilobectomy | 64 (0.9 %) | 16 (1.9%) | 1.88 [1.20–2.94] | |
| Pneumonectomy | 21 (0.3 %) | 16 (1.9%) | 40.70 [4.75–348.64] | |
| Segmentectomy | 1186 (16.7 %) | 89 (10.5%) | 0.61 [0.51–0.75] | |
| cT stage | 0.043 | |||
| T1 | 4956 (69.8 %) | 547 (64.8%) | ||
| T1a | 1 | |||
| T1b | 1.19 [0.99–1.43] | |||
| T1c | 1.23 [0.94–1.59] | |||
| T2 | 1661 (23.4%) | 215 (25.5%) | ||
| T2a | 1.22 [0.99–1.49] | |||
| T2b | 1.38 [0.95–1.99] | |||
| T3 | 391 (5.5 %) | 67 (8.0%) | 1.38 [1.02–1.87] | |
| T4 | 92 (1.3%) | 14 (1.7%) | 2.06 [1.16–3.65] | |
| Tis | 0.67 [0.16–2.84] | |||
| cN stage | <0.0001 | |||
| cN0 | 6638 (93.5 %) | 741 (87.9%) | 1 | |
| cN1 | 277 (3.9 %) | 69 (8.2%) | 2.04 [1.55–2.69] | |
| cN2 | 178 (2.5 %) | 31 (3.7%) | 1.27 [0.84–1.91] | |
| cN3 | 7 (0.1 %) | 2 (0.2%) | 4.42 [0.81–24.18] |
| Variable . | Full VATS group, n = 7100 . | Conversion group, n = 843 . | Odds ratio [95% CI] . | P-value . |
|---|---|---|---|---|
| Sex | <0.0001 | |||
| Female | 3032 (42.6 %) | 289 (34.2 %) | 1 | |
| Male | 4068 (57.3%) | 554 (65.8 %) | 1.42 [1.25–1.60] | |
| Age (years) | 69 ± 11.3 | 66.0 ± 9.7 | 1.012 [1.006–1.018] | 0.0002 |
| BMI (kg/m²) | 25.3 ± 4.6 | 26.2 ± 5.0 | 1.039 [1.026–1.052] | <0.0001 |
| WHO PS | 0.007 | |||
| 0 | 4366 (61.5%) | 497 (59.0%) | 1 | |
| 1 | 2385 (33.6 %) | 297 (35.5%) | 1.19 [1.05–1.35] | |
| 2 | 319 (4.5 %) | 44 (5.2%) | 1.14 [0.85–1.52] | |
| 3 | 28 (0.4%) | 4 (0.4%) | 1.93 [0.85–4.38] | |
| 4 | 0 (0%) | 1 (< 0.1%) | ||
| ASA status | <0.0001 | |||
| ASA 1-2 | 4785 (67.4%) | 520 (61.7%) | 1 | |
| ASA 3-4 | 2315 (32.6%) | 323 (38.3%) | 1.32 [1.17–1.50] | |
| History of smoking | 5495 (77.4%) | 697 (82.6%) | 1.22 [1.08–1.37] | 0.001 |
| Smoking (pack-years) | 30 ± 14.1 | 34.4 ± 25.0 | 1.005 [1.003–1.008] | <0.0001 |
| Preop. FEV1 | 90 ± 19.6 | 87.7 ± 19.3 | 0.993 [0.990–0.996] | <0.0001 |
| Induction CTx | 134 (1.9 %) | 19 (2.1%) | 0.809 | |
| Hypertension | 2201 (31 %) | 293 (34.8%) | 1.19 [1.05–1.35] | 0.007 |
| Pulmonary hypertension | 7 (< 0.1 %) | 1 (< 0.1%) | 0.275 | |
| Congestive heart failure | 28 (0.4 %) | 6 (0.7%) | 0.791 | |
| Peripheral arterial disease | 646 (9.1 %) | 110 (13.1%) | 1.37 [1.14–1.64] | 0.001 |
| Valvulopathy | 78 (1.1 %) | 14 (1.7%) | 1.74 [1.04–2.90] | 0.034 |
| Coronary artery disease | 646 (9.1 %) | 107 (12.7%) | 1.34 [1.11–1.63] | 0.003 |
| Cardiac arrhythmia | 475 (6.7 %) | 76 (9.1%) | 1.31 [1.04–1.64] | 0.022 |
| Previous cardiac surgery | 85 (1.2 %) | 18 (2.2%) | 1.75 [1.14–2.70] | 0.011 |
| Stroke | 244 (3.3 %) | 39 (4.6%) | 1.40 [1.04–1.88] | 0.025 |
| Antiplatelet therapy | 320 (4.5 %) | 53 (6.3%) | 1.45 [1.12–1.87] | 0.005 |
| Asthma | 128 (1.8 %) | 22 (2.5%) | 0.220 | |
| Sleep apnoea | 198 (2.8 %) | 26 (3.1%) | 0.674 | |
| Previous thoracic surgery | 142 (2.0 %) | 20 (2.4%) | 1.12 [0.77–1.63] | 0.541 |
| Previous thoracic trauma | 7 (< 0.1 %) | 6 (0.7%) | 3.34 [1.39–8] | 0.007 |
| Alcohol addiction | 334 (4.7 %) | 47 (5.6%) | 0.826 | |
| Chronic kidney failure | 134 (1.9%) | 33 (3.9%) | 2.32 [1.70–3.17] | <0.0001 |
| Malnutrition | 45 (0.6%) | 7 (0.9%) | 0.597 | |
| Thyroid dysfunction | 270 (3.8 %) | 34 (4.1%) | 0.295 | |
| Drug addiction | 45 (0.6 %) | 12 (1.4%) | 1.55 [0.81–2.94] | 0.186 |
| Chronic liver failure | 41 (0.6 %) | 7 (0.8%) | 0.527 | |
| Type II diabetes | 724 (10.2 %) | 130 (15.4%) | 1.42 [1.19–1.69] | <0.0001 |
| Histological analysis | <0.0001 | |||
| Primary lung | 6688 (94.2 %) | 811 (96.2%) | 1 | |
| Metastasis | 292 (4.1 %) | 24 (2.9%) | 0.63 [0.48–0.83] | |
| Benign | 120 (1.7 %) | 8 (0.9%) | 0.40 [0.23–0.69] | |
| Surgery side | ||||
| Right | 3684 (51.9%) | 423 (50.2%) | 0.257 | |
| Left | 3416 (48.1%) | 420 (49.8%) | ||
| Extent of resection | <0.0001 | |||
| Lobectomy | 5829 (82.1 %) | 722 (85.7%) | 1 | |
| Bilobectomy | 64 (0.9 %) | 16 (1.9%) | 1.88 [1.20–2.94] | |
| Pneumonectomy | 21 (0.3 %) | 16 (1.9%) | 40.70 [4.75–348.64] | |
| Segmentectomy | 1186 (16.7 %) | 89 (10.5%) | 0.61 [0.51–0.75] | |
| cT stage | 0.043 | |||
| T1 | 4956 (69.8 %) | 547 (64.8%) | ||
| T1a | 1 | |||
| T1b | 1.19 [0.99–1.43] | |||
| T1c | 1.23 [0.94–1.59] | |||
| T2 | 1661 (23.4%) | 215 (25.5%) | ||
| T2a | 1.22 [0.99–1.49] | |||
| T2b | 1.38 [0.95–1.99] | |||
| T3 | 391 (5.5 %) | 67 (8.0%) | 1.38 [1.02–1.87] | |
| T4 | 92 (1.3%) | 14 (1.7%) | 2.06 [1.16–3.65] | |
| Tis | 0.67 [0.16–2.84] | |||
| cN stage | <0.0001 | |||
| cN0 | 6638 (93.5 %) | 741 (87.9%) | 1 | |
| cN1 | 277 (3.9 %) | 69 (8.2%) | 2.04 [1.55–2.69] | |
| cN2 | 178 (2.5 %) | 31 (3.7%) | 1.27 [0.84–1.91] | |
| cN3 | 7 (0.1 %) | 2 (0.2%) | 4.42 [0.81–24.18] |
ASA: American Society of Anesthesiologists; BMI: body mass index; CTx: chemotherapy; preop. FEV1: preoperative forced expiratory volume in 1 s;. WHO PS: World Health Organization performance status.
A univariate analysis of the preoperative characteristics of patients treated with anatomical lung resection with full video-assisted thoracoscopic surgery or intraoperative conversion to thoracotomy
| Variable . | Full VATS group, n = 7100 . | Conversion group, n = 843 . | Odds ratio [95% CI] . | P-value . |
|---|---|---|---|---|
| Sex | <0.0001 | |||
| Female | 3032 (42.6 %) | 289 (34.2 %) | 1 | |
| Male | 4068 (57.3%) | 554 (65.8 %) | 1.42 [1.25–1.60] | |
| Age (years) | 69 ± 11.3 | 66.0 ± 9.7 | 1.012 [1.006–1.018] | 0.0002 |
| BMI (kg/m²) | 25.3 ± 4.6 | 26.2 ± 5.0 | 1.039 [1.026–1.052] | <0.0001 |
| WHO PS | 0.007 | |||
| 0 | 4366 (61.5%) | 497 (59.0%) | 1 | |
| 1 | 2385 (33.6 %) | 297 (35.5%) | 1.19 [1.05–1.35] | |
| 2 | 319 (4.5 %) | 44 (5.2%) | 1.14 [0.85–1.52] | |
| 3 | 28 (0.4%) | 4 (0.4%) | 1.93 [0.85–4.38] | |
| 4 | 0 (0%) | 1 (< 0.1%) | ||
| ASA status | <0.0001 | |||
| ASA 1-2 | 4785 (67.4%) | 520 (61.7%) | 1 | |
| ASA 3-4 | 2315 (32.6%) | 323 (38.3%) | 1.32 [1.17–1.50] | |
| History of smoking | 5495 (77.4%) | 697 (82.6%) | 1.22 [1.08–1.37] | 0.001 |
| Smoking (pack-years) | 30 ± 14.1 | 34.4 ± 25.0 | 1.005 [1.003–1.008] | <0.0001 |
| Preop. FEV1 | 90 ± 19.6 | 87.7 ± 19.3 | 0.993 [0.990–0.996] | <0.0001 |
| Induction CTx | 134 (1.9 %) | 19 (2.1%) | 0.809 | |
| Hypertension | 2201 (31 %) | 293 (34.8%) | 1.19 [1.05–1.35] | 0.007 |
| Pulmonary hypertension | 7 (< 0.1 %) | 1 (< 0.1%) | 0.275 | |
| Congestive heart failure | 28 (0.4 %) | 6 (0.7%) | 0.791 | |
| Peripheral arterial disease | 646 (9.1 %) | 110 (13.1%) | 1.37 [1.14–1.64] | 0.001 |
| Valvulopathy | 78 (1.1 %) | 14 (1.7%) | 1.74 [1.04–2.90] | 0.034 |
| Coronary artery disease | 646 (9.1 %) | 107 (12.7%) | 1.34 [1.11–1.63] | 0.003 |
| Cardiac arrhythmia | 475 (6.7 %) | 76 (9.1%) | 1.31 [1.04–1.64] | 0.022 |
| Previous cardiac surgery | 85 (1.2 %) | 18 (2.2%) | 1.75 [1.14–2.70] | 0.011 |
| Stroke | 244 (3.3 %) | 39 (4.6%) | 1.40 [1.04–1.88] | 0.025 |
| Antiplatelet therapy | 320 (4.5 %) | 53 (6.3%) | 1.45 [1.12–1.87] | 0.005 |
| Asthma | 128 (1.8 %) | 22 (2.5%) | 0.220 | |
| Sleep apnoea | 198 (2.8 %) | 26 (3.1%) | 0.674 | |
| Previous thoracic surgery | 142 (2.0 %) | 20 (2.4%) | 1.12 [0.77–1.63] | 0.541 |
| Previous thoracic trauma | 7 (< 0.1 %) | 6 (0.7%) | 3.34 [1.39–8] | 0.007 |
| Alcohol addiction | 334 (4.7 %) | 47 (5.6%) | 0.826 | |
| Chronic kidney failure | 134 (1.9%) | 33 (3.9%) | 2.32 [1.70–3.17] | <0.0001 |
| Malnutrition | 45 (0.6%) | 7 (0.9%) | 0.597 | |
| Thyroid dysfunction | 270 (3.8 %) | 34 (4.1%) | 0.295 | |
| Drug addiction | 45 (0.6 %) | 12 (1.4%) | 1.55 [0.81–2.94] | 0.186 |
| Chronic liver failure | 41 (0.6 %) | 7 (0.8%) | 0.527 | |
| Type II diabetes | 724 (10.2 %) | 130 (15.4%) | 1.42 [1.19–1.69] | <0.0001 |
| Histological analysis | <0.0001 | |||
| Primary lung | 6688 (94.2 %) | 811 (96.2%) | 1 | |
| Metastasis | 292 (4.1 %) | 24 (2.9%) | 0.63 [0.48–0.83] | |
| Benign | 120 (1.7 %) | 8 (0.9%) | 0.40 [0.23–0.69] | |
| Surgery side | ||||
| Right | 3684 (51.9%) | 423 (50.2%) | 0.257 | |
| Left | 3416 (48.1%) | 420 (49.8%) | ||
| Extent of resection | <0.0001 | |||
| Lobectomy | 5829 (82.1 %) | 722 (85.7%) | 1 | |
| Bilobectomy | 64 (0.9 %) | 16 (1.9%) | 1.88 [1.20–2.94] | |
| Pneumonectomy | 21 (0.3 %) | 16 (1.9%) | 40.70 [4.75–348.64] | |
| Segmentectomy | 1186 (16.7 %) | 89 (10.5%) | 0.61 [0.51–0.75] | |
| cT stage | 0.043 | |||
| T1 | 4956 (69.8 %) | 547 (64.8%) | ||
| T1a | 1 | |||
| T1b | 1.19 [0.99–1.43] | |||
| T1c | 1.23 [0.94–1.59] | |||
| T2 | 1661 (23.4%) | 215 (25.5%) | ||
| T2a | 1.22 [0.99–1.49] | |||
| T2b | 1.38 [0.95–1.99] | |||
| T3 | 391 (5.5 %) | 67 (8.0%) | 1.38 [1.02–1.87] | |
| T4 | 92 (1.3%) | 14 (1.7%) | 2.06 [1.16–3.65] | |
| Tis | 0.67 [0.16–2.84] | |||
| cN stage | <0.0001 | |||
| cN0 | 6638 (93.5 %) | 741 (87.9%) | 1 | |
| cN1 | 277 (3.9 %) | 69 (8.2%) | 2.04 [1.55–2.69] | |
| cN2 | 178 (2.5 %) | 31 (3.7%) | 1.27 [0.84–1.91] | |
| cN3 | 7 (0.1 %) | 2 (0.2%) | 4.42 [0.81–24.18] |
| Variable . | Full VATS group, n = 7100 . | Conversion group, n = 843 . | Odds ratio [95% CI] . | P-value . |
|---|---|---|---|---|
| Sex | <0.0001 | |||
| Female | 3032 (42.6 %) | 289 (34.2 %) | 1 | |
| Male | 4068 (57.3%) | 554 (65.8 %) | 1.42 [1.25–1.60] | |
| Age (years) | 69 ± 11.3 | 66.0 ± 9.7 | 1.012 [1.006–1.018] | 0.0002 |
| BMI (kg/m²) | 25.3 ± 4.6 | 26.2 ± 5.0 | 1.039 [1.026–1.052] | <0.0001 |
| WHO PS | 0.007 | |||
| 0 | 4366 (61.5%) | 497 (59.0%) | 1 | |
| 1 | 2385 (33.6 %) | 297 (35.5%) | 1.19 [1.05–1.35] | |
| 2 | 319 (4.5 %) | 44 (5.2%) | 1.14 [0.85–1.52] | |
| 3 | 28 (0.4%) | 4 (0.4%) | 1.93 [0.85–4.38] | |
| 4 | 0 (0%) | 1 (< 0.1%) | ||
| ASA status | <0.0001 | |||
| ASA 1-2 | 4785 (67.4%) | 520 (61.7%) | 1 | |
| ASA 3-4 | 2315 (32.6%) | 323 (38.3%) | 1.32 [1.17–1.50] | |
| History of smoking | 5495 (77.4%) | 697 (82.6%) | 1.22 [1.08–1.37] | 0.001 |
| Smoking (pack-years) | 30 ± 14.1 | 34.4 ± 25.0 | 1.005 [1.003–1.008] | <0.0001 |
| Preop. FEV1 | 90 ± 19.6 | 87.7 ± 19.3 | 0.993 [0.990–0.996] | <0.0001 |
| Induction CTx | 134 (1.9 %) | 19 (2.1%) | 0.809 | |
| Hypertension | 2201 (31 %) | 293 (34.8%) | 1.19 [1.05–1.35] | 0.007 |
| Pulmonary hypertension | 7 (< 0.1 %) | 1 (< 0.1%) | 0.275 | |
| Congestive heart failure | 28 (0.4 %) | 6 (0.7%) | 0.791 | |
| Peripheral arterial disease | 646 (9.1 %) | 110 (13.1%) | 1.37 [1.14–1.64] | 0.001 |
| Valvulopathy | 78 (1.1 %) | 14 (1.7%) | 1.74 [1.04–2.90] | 0.034 |
| Coronary artery disease | 646 (9.1 %) | 107 (12.7%) | 1.34 [1.11–1.63] | 0.003 |
| Cardiac arrhythmia | 475 (6.7 %) | 76 (9.1%) | 1.31 [1.04–1.64] | 0.022 |
| Previous cardiac surgery | 85 (1.2 %) | 18 (2.2%) | 1.75 [1.14–2.70] | 0.011 |
| Stroke | 244 (3.3 %) | 39 (4.6%) | 1.40 [1.04–1.88] | 0.025 |
| Antiplatelet therapy | 320 (4.5 %) | 53 (6.3%) | 1.45 [1.12–1.87] | 0.005 |
| Asthma | 128 (1.8 %) | 22 (2.5%) | 0.220 | |
| Sleep apnoea | 198 (2.8 %) | 26 (3.1%) | 0.674 | |
| Previous thoracic surgery | 142 (2.0 %) | 20 (2.4%) | 1.12 [0.77–1.63] | 0.541 |
| Previous thoracic trauma | 7 (< 0.1 %) | 6 (0.7%) | 3.34 [1.39–8] | 0.007 |
| Alcohol addiction | 334 (4.7 %) | 47 (5.6%) | 0.826 | |
| Chronic kidney failure | 134 (1.9%) | 33 (3.9%) | 2.32 [1.70–3.17] | <0.0001 |
| Malnutrition | 45 (0.6%) | 7 (0.9%) | 0.597 | |
| Thyroid dysfunction | 270 (3.8 %) | 34 (4.1%) | 0.295 | |
| Drug addiction | 45 (0.6 %) | 12 (1.4%) | 1.55 [0.81–2.94] | 0.186 |
| Chronic liver failure | 41 (0.6 %) | 7 (0.8%) | 0.527 | |
| Type II diabetes | 724 (10.2 %) | 130 (15.4%) | 1.42 [1.19–1.69] | <0.0001 |
| Histological analysis | <0.0001 | |||
| Primary lung | 6688 (94.2 %) | 811 (96.2%) | 1 | |
| Metastasis | 292 (4.1 %) | 24 (2.9%) | 0.63 [0.48–0.83] | |
| Benign | 120 (1.7 %) | 8 (0.9%) | 0.40 [0.23–0.69] | |
| Surgery side | ||||
| Right | 3684 (51.9%) | 423 (50.2%) | 0.257 | |
| Left | 3416 (48.1%) | 420 (49.8%) | ||
| Extent of resection | <0.0001 | |||
| Lobectomy | 5829 (82.1 %) | 722 (85.7%) | 1 | |
| Bilobectomy | 64 (0.9 %) | 16 (1.9%) | 1.88 [1.20–2.94] | |
| Pneumonectomy | 21 (0.3 %) | 16 (1.9%) | 40.70 [4.75–348.64] | |
| Segmentectomy | 1186 (16.7 %) | 89 (10.5%) | 0.61 [0.51–0.75] | |
| cT stage | 0.043 | |||
| T1 | 4956 (69.8 %) | 547 (64.8%) | ||
| T1a | 1 | |||
| T1b | 1.19 [0.99–1.43] | |||
| T1c | 1.23 [0.94–1.59] | |||
| T2 | 1661 (23.4%) | 215 (25.5%) | ||
| T2a | 1.22 [0.99–1.49] | |||
| T2b | 1.38 [0.95–1.99] | |||
| T3 | 391 (5.5 %) | 67 (8.0%) | 1.38 [1.02–1.87] | |
| T4 | 92 (1.3%) | 14 (1.7%) | 2.06 [1.16–3.65] | |
| Tis | 0.67 [0.16–2.84] | |||
| cN stage | <0.0001 | |||
| cN0 | 6638 (93.5 %) | 741 (87.9%) | 1 | |
| cN1 | 277 (3.9 %) | 69 (8.2%) | 2.04 [1.55–2.69] | |
| cN2 | 178 (2.5 %) | 31 (3.7%) | 1.27 [0.84–1.91] | |
| cN3 | 7 (0.1 %) | 2 (0.2%) | 4.42 [0.81–24.18] |
ASA: American Society of Anesthesiologists; BMI: body mass index; CTx: chemotherapy; preop. FEV1: preoperative forced expiratory volume in 1 s;. WHO PS: World Health Organization performance status.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
